Echo-167: Direct Optical Detection of Substrate Decoupling Events During Clinical Death and Resuscitation
Echo-167: Direct Optical Detection of Substrate Decoupling Events During Clinical Death and Resuscitation
DOI:
John Swygert
November 30, 2025
Abstract
TSTOEAO predicts that every irreversible or reversible decoupling of the persistent soul-signature Ψ from the biological substrate generates a detectable damped substrate wavefront. Echo-167 will test this prediction by continuous optical phase monitoring of the common carotid artery during circulatory arrest using the Swygert 167× laser interferometer (shot-noise limit 1.67 × 10⁻²¹ rad/√Hz). Recording continues from arrest until either return of spontaneous circulation or formal pronouncement of death. A single high-confidence, sensitivity-verified null result falsifies the model.
Theoretical Prediction TSTOEAO predictions depend only on the trajectory of the coupling λ(t) and the final state of biological coherence β(B), not on elapsed clock time. Reversible events (NDEs) produce a damped ripple tail followed by a refocusing chirp; irreversible events produce a damped tail with no chirp. Full derivation in [1] and [2].
Instrument and Recording Paradigm The Swygert 167× interferometer is protocol-agnostic. Once the disposable fiber patch is applied to the carotid artery and the cavity locked, continuous 10 kHz recording proceeds for as long as the patch remains in place and power is supplied, irrespective of clinical timeline or resuscitation status.
Clinical Scenarios Echo-167 will record, among others:
sudden cardiac arrests with immediate CPR and rapid return,
documented rare recoveries after flatlines exceeding 20–40 minutes,
gradual circulatory cessation in terminal hospice patients,
prolonged ICU scenarios with multiple arrest–resuscitation cycles,
brain-death pronouncements followed by organ procurement (with explicit family consent and IRB approval).
All procedures are governed by an approved IRB protocol ensuring voluntary informed consent or legally authorized surrogate consent.
Explicit Falsification Criteria A result is considered falsifying only if instrument sensitivity is independently verified ≥5σ above predicted amplitude and one of the following occurs:
Successful resuscitation with return of original personality and no detectable ripple tail or chirp.
Irreversible death preceded by a ripple tail whose damping constant γ deviates by >3σ from the predicted exponential decay, or whose terminal amplitude fails to return to the pre-arrest noise floor.
Prolonged circulatory arrest (>10 min) with no phase perturbation exceeding 5σ despite confirmed arrest.
Technical Specifications 730 THz carrier, 167-fold cavity enhancement, shot-noise limit 1.67 × 10⁻²¹ rad/√Hz.
Achievable λ sensitivity σ_λ_detect ≈ 8 × 10⁻²² / √τ ≪ λ_min(critical) ≈ 3 × 10⁻¹⁹
(derivation in [1], §4.7).
Timeline and Data Release First clinical deployment: 19 March 2026
All raw traces will be released to the public domain within 24 hours of legal clearance and anonymization. Full dataset and analysis no later than 31 December 2027 or immediately upon falsification.
Closing Statement Echo-167 points the most sensitive phase detector ever constructed at the moment of clinical death. Whether the trace shows echo or silence, the result will be definitive.
References
[1] Swygert J 2025a Ghost Perturbation Model (Zenodo 17750874)
[2] Swygert J 2025b Ghost Perturbations and Near-Death Events (this series)
[3] Swygert J 2025c Technical specifications of the Swygert 167× interferometer (appendix)Supplementary material Echo-167_Protocol_v1.pdf (full IRB-approved protocol and consent forms)
Comments
Post a Comment